FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.
What happened
FDA inspected the Taizhou, Jiangsu, China facility from March 10 to March 14, 2025, and found violations of current good manufacturing practice (CGMP) for finished drugs, including products labeled sterile that were not sterilized and were not sterility tested. FDA also found problems with high-performance liquid chromatography (HPLC) and gas chromatography (GC) testing and data controls, including shared accounts, unretained or deleted Excel worksheets, and use of unvalidated Excel for product release. A records review also found over-the-counter product active-ingredient concentrations above the allowable range for that over-the-counter drug type.
What FDA found
The firm lacked procedures to prevent microbial contamination in drug products it labeled sterile.
21 CFR 211.113(b)Drug products labeled sterile were not sterilized, and the firm did not perform sterility testing.
21 CFR 211.113(b)HPLC assay testing lacked proper system suitability checks and used a standard-curve frequency that could mask system drift.
21 CFR 211.160(b)The firm did not extend its revised standard-curve testing to GC assay testing.
21 CFR 211.160(b)GC/HPLC data controls were inadequate: Excel calculations were not retained or were deleted, accounts were shared, and unvalidated Excel was used for release.
21 CFR 211.160(b)OTC product process controls allowed active-ingredient concentrations above the allowable range for that OTC drug type.
section 505G of the FD&C Act
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrections and prevention, including a comprehensive data-integrity investigation, a risk assessment, and a global corrective and preventive action plan (CAPA), and to notify FDA before resuming drug manufacturing.
Who should pay attention
- U.S. pharmacies and distributors selling over-the-counter drugs from this firm
- companies using this firm as a contract drug manufacturer
- quality teams managing supplier qualification, sterility claims, and data integrity
This is a summary. Read the original letter on fda.gov.